Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Experimental: Dose Escalation of VIP236

Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer

Drug: VIP236

VIP236 is a small molecule drug conjugate (SMDC) consisting of an alpha v beta 3 (αVβ3) integrin binder linked to an optimized camptothecin (CPT) compound (VIP126), which is released by the enzyme neutrophil elastase (NE) in the tumor microenvironment (TME).

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 7, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments